Research
Hormonal
GLP-1 receptor agonists may enhance the weight loss and metabolic benefits of adjustable gastric banding (AGB) by mimicking the hormonal effects of more invasive surgeries like Roux-en-Y gastric bypass.
Research suggests that combining GLP-1 medications with Adjustable Gastric Banding might improve weight loss results. However, this is still experimental, and you should discuss the risks (like pancreatitis) and benefits with your surgeon.
LimitedConditionalLOW confidence
GLP-1 receptor agonist enhances the surgically induced decreases in body weight and adiposity after AGB... GLP-1 receptor agonists might find new clinical utility as the pharmaceutical component of a pharmaco-surgical approach for optimizing AGB
Why this rating
Based on preclinical (rat) studies and extrapolation to humans; requires confirmation in large-scale clinical trials.
Source
Synthetic agents in the context of metabolic/bariatric surgery: expanding the scope and impact of diabetes drug discovery
David R. Janero · Expert Opinion on Drug Discovery · 2014
DOI 10.1517/17460441.2014.876988
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery is not a guaranteed cure for type 2 diabetes, with significant rates of non-remission (20-40%) and recurrence (up to 50% at 10 years) occurring even after successful weight loss.Good
- Preoperative glycemic control using synthetic oral hypoglycemic drugs significantly reduces the risk of T2D recurrence after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →